Journal
CELL REPORTS
Volume 37, Issue 6, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2021.109979
Keywords
-
Categories
Funding
- BBSRC
- Wellcome
- University of Manchester Strategic Fund
- Christie Charitable Fund
- CRUK Manchester Institute [A20971, A27412]
- Manchester CRUK Centre Award [A25254]
- CRUK Manchester Experimental Cancer Medicines Centre [A25146]
- CRUK Lung Cancer Centre of Excellence [A20465]
Ask authors/readers for more resources
The study shows that the TIAM1-RAC1 signaling pathway promotes survival of SCLC cells through nuclear sequestration of Nur77.
Small-cell lung cancer (SCLC), an aggressive neuroendocrine malignancy, has limited treatment options beyond platinum-based chemotherapy, whereafter acquired resistance is rapid and common. By analyzing expression data from SCLC tumors, patient-derived models, and established cell lines, we show that the expression of TIAM1, an activator of the small GTPase RAC1, is associated with a neuroendocrine gene program. TIAM1 depletion or RAC1 inhibition reduces viability and tumorigenicity of SCLC cells by increasing apoptosis associated with conversion of BCL2 from its pro-survival to pro-apoptotic function via BH3 domain exposure. This conversion is dependent upon cytoplasmic translocation of Nur77, an orphan nuclear receptor. TIAM1 interacts with and sequesters Nur77 in SCLC cell nuclei and TIAM1 depletion or RAC1 inhibition promotes Nur77 translocation to the cytoplasm. Mutant TIAM1 with reduced Nur77 binding fails to suppress apoptosis triggered by TIAM1 depletion. In conclusion, TIAM1-RAC1 signaling promotes SCLC cell survival via Nur77 nuclear sequestration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available